Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ERCC5	2073	PHENYLTHIOUREA	CHEMBL263376		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ERCC5	rs2094258	T	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele T is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.	28796378	1448926535
ERCC5	rs751402	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926524
ERCC5	rs2296147	C	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.	28796378	1448926546
ERCC5	rs1047768	C	Platinum compounds	efficacy	no	No significant relationship between genotype and drug response was detected.	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	22761669	982046461
ERCC5	rs17655	GG	platinum	efficacy	yes	significant in subset of Asian studies. GG+GC vs. CC was not significant. G vs C was trend.	Genotype GG is associated with increased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	28314991	1448635155
ERCC5	rs1047768	C	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.	28796378	1448926507
ERCC5	rs873601	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926557
ERCC5	rs17655	C	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele C is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926513